Abstract
Maraviroc (Selzentry; Pfizer) is a small-molecule drug that inhibits HIV-1 entry by blocking the interaction between HIV-1 and the chemokine receptor CCR5 on host cells. It became the first drug in its class to be approved by the US FDA for the treatment of patients with CCR5-tropic HIV-1 in combination with other antiretroviral agents in August 2007, and it was approved in Europe (where its trade name is Celsentri) in September 2007.
This is a preview of subscription content, log in via an institution to check access.
References
Flexner, C. HIV drug development: the next 25 years. Nature Rev. Drug Disc. 6, 959–966 (2007).
Tsibris, A. M. & Kuritzkes, D. R. Chemokine antagonists as therapeutics: focus on HIV-1. Annu. Rev. Med. 58, 445–459 (2007).
Dorr, P. et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 49, 4721–4732 (2005).
Food and Drug Administration. FDA labelling information [online], (2007).
Fätkenheuer, G. et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nature Med. 11, 1170–1172 (2005).
European Medicines Agency. European Public Assessment Report [online], (2007).
Clumeck, N. et al. A multicenter, randomized, double-blind, comparative rial of a novel CCR5 antagonist, maraviroc versus efavirenz, both in combination with Combivir (zidovudine [ZDV]/lamivudine [3TC]), for the treatment of antiretroviral naive subjects infected with R5 HIV-1: week 48 results of the MERIT study. 4th IAS Conference on HIV Pathogeneis, Treatment and Prevention, Sydney, Australia, July 22–25 [Abstract WESS104]. IAS2007.org web site[online], (2007).
Reeves, J. D. et al. Enhancements to the Trofile HIV coreceptor tropism assay enable reliable detection of CXCR4-using subpopulations at less than 1%. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 17–20 [Abstract H-1026]. American Society of Microbiology web site[online], (2007)
Wilkin, T. J. et al. Chemokine coreceptor tropism among antiretroviral-experienced patients screening for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group 5211. Clin. Infect. Dis. 44, 591–595 (2007).
Koot, M. et al. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann. Intern. Med. 118, 681–688 (1993).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
D. K. is a consultant to Pfizer, Schering-Plough and Monogram, and receives research support from Schering-Plough and Human Genome Sciences.
Rights and permissions
About this article
Cite this article
Kuritzkes, D., Kar, S. & Kirkpatrick, P. Maraviroc. Nat Rev Drug Discov 7, 15–16 (2008). https://doi.org/10.1038/nrd2490
Issue Date:
DOI: https://doi.org/10.1038/nrd2490
- Springer Nature Limited
This article is cited by
-
The chemokine receptor CCR5: multi-faceted hook for HIV-1
Retrovirology (2024)
-
Encouraging an excitable brain state: mechanisms of brain repair in stroke
Nature Reviews Neuroscience (2021)
-
Luteolin: a blocker of SARS-CoV-2 cell entry based on relaxed complex scheme, molecular dynamics simulation, and metadynamics
Journal of Molecular Modeling (2021)
-
Use of In Vitro to In Vivo Extrapolation to Predict the Optimal Strategy for Patients Switching from Efavirenz to Maraviroc or Nevirapine
Clinical Pharmacokinetics (2015)
-
Computational study and peptide inhibitors design for the CDK9 – cyclin T1 complex
Journal of Molecular Modeling (2013)